Dexcom G5 Mobile already available on Android

Novalab Ibérica S.A., recently belonging to the Air Liquid Healthcare group, which distributes in Spain and Portugal the continuous glucose monitoring systems DEXCOM has confirmed the availability in Spain of the Dexcom G5 Mobile system on Android platform.

The Dexcom G5 Mobile system continuously and directly allows the glucose of people with diabetes by sending the data to a mobile terminal (Apple and some Android) showing not only the current value, but also the tendency and speed of glucose change, which helps to make informed decisions about therapeutic changes.

Additionally, it is capable of emitting alerts and alarm when glucose reaches unwanted values, which is very important especially to avoid the dreaded hypoglycemia.From the mobile phone with the Dexcom Follow app you can send an image of the data to other mobile phones, so that up to five relatives can follow up simultaneously.On the other hand, the Glooko-Diasend application also collects the data and allows them to be consulted by the health professionals that follow the patient.

A study carried out by the Imperial Colleage of London [1] has shown that the Dexcom G5 not only decreases the time in hypoglycemia but also significantly reduces the fear that people with diabetes have, which often prevents many timesthe necessary adjustments for good metabolic control.

The Dexcom G5 Mobile is the only system of its characteristics that has been approved by the European health authorities and by the American FDA, to be able to make therapeutic decisions without the need for confirmation with capillary glycems and for use in diabetic people from two yearsAgeAlso a clinical study replace-bg [2] has corroborated that it is feasible in the usual practice.

Other very recent clinical studies and sufficient entity such as Comisair [3], Gold [4] or Diamond [5] have confirmed the effectiveness of continuous glucose monitoring in patients, not only with expensive and sophisticated systems such as bombs such as bombsof insulin, but with common therapies based on multiple insulin injections.

[1] Diab, Tech. & Amp; ter.2017 (19) [Supp.1].A-15 (OP 036).
[2] Diab.Care.2017. DOI: 10.2337/DC16-2482.
[3] Diab.Tech. & Amp;Ter.2016;18 (9).532-8.
[4] Jama.2017; 317 (4): 379-387.
[5] Jama.2017; 317 (4): 371-378

But the most important news of the call was the update of the Dexcom product line.The company plans to launch an updated version of the G5 transmitter, which is currently being reviewed, at the end of this year.The update will include a new more reliable touch screen receiver, a new insertion system and the corresponding smaller transmitter, an Android platform and additional application functions, including the incorporation of insulin data.

I forgot, last year Dexcom 171 million American benefit dollars, 40% more than the previous year ... 8- |